Recent News

• 03.06.2026 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.02.2026 - UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.02.2026 - UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
• 02.27.2026 - ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
• 02.24.2026 - UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
• 02.23.2026 - UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
• 01.05.2026 - Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
• 12.05.2025 - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.02.2026 - 8-K Current report
• 03.02.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.02.2026 - EX-99.1 EX-99.1
• 03.02.2026 - 8-K Current report
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities